A series of clinical trials evaluating the Medtronic CoreValve/Evolut TAVR system. The Evolut Low Risk trial demonstrated TAVR was noninferior to surgery even in low-risk patients, further expanding the indications for transcatheter valve replacement.
A series of clinical trials evaluating the Medtronic CoreValve/Evolut TAVR system. The Evolut Low Risk trial demonstrated TAVR was noninferior to surgery even in low-risk patients, further expanding the indications for transcatheter valve replacement.
Our Heart Team provides expert second opinions with plain-language explanations. 24-hour turnaround.